CoChat

Brain high-throughput multi-omics data reveal molecular heterogeneity in Alzheimer’s disease

Open access

The DOI matches its Crossref record; 187 of the 187 references it cites were found in a registry or an index.

Abstract

Unbiased data-driven omic approaches are revealing the molecular heterogeneity of Alzheimer disease. Here, we used machine learning approaches to integrate high-throughput transcriptomic, proteomic, metabolomic, and lipidomic profiles with clinical and neuropathological data from multiple human AD cohorts. We discovered 4 unique multimodal molecular profiles, one of them showing signs of poor cognitive function, a faster pace of disease progression, shorter survival with the disease, severe neurodegeneration and astrogliosis, and reduced levels of metabolomic profiles. We found this molecular profile to be present in multiple affected cortical regions associated with higher Braak tau scores and significant dysregulation of synapse-related genes, endocytosis, phagosome, and mTOR signaling pathways altered in AD early and late stages. AD cross-omics data integration with transcriptomic data from an SNCA mouse model revealed an overlapping signature. Furthermore, we leveraged single-nuclei RNA-seq data to identify distinct cell-types that most likely mediate molecular profiles. Lastly, we identified that the multimodal clusters uncovered cerebrospinal fluid biomarkers poised to monitor AD progression and possibly cognition. Our cross-omics analyses provide novel critical molecular insights into AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pbio.3002607

Cites

187 of 187 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Study design. . The transcriptomics, proteomics, metabolomics, and lipidomics profiles of postmortem parietal cortex samples from the Knight ADRC participants were used. The 3 omics shared 278 subjects (255 sporadic AD and 23 control cases). Expression/reading matrices were prepared for the same set of samples (n = 278) and different numbers of features (features = 60,754, proteins = 1,092, metabolites = 627). Before the integration, feature selection was performed on all omics datasets whose number of features exceeded 1,000 by selecting the top and most variant features. A Bayesian integrative clustering method was then employed to integrate the 3 omics datasets and the best clustering solution was extracted based on the maximum deviance ratio and the minimum BIC. AD molecular profiles were then linked to multiple clinical and molecular attributes to examine whether an association with these attributes exists. In addition, survival, DE, cell type-specific effect, and cell proportions inference analyses were performed on these profiles. These molecular profiles were then replicated in 2 independent datasets from MSBB BM36 (AD = 93, CO = 23) and ROSMAP (AD = 144, CO = 93). Dysregulated synaptic genes in the Knight-C4 profile were extracted and used for downstream AD staging analyses and in the ROSMAP cohort (early-AD vs. control and late-AD vs. control). Common synaptic genes present in the CSF SOMA dataset and associated with an increased risk of dementia through survival analyses were identified as CSF synaptic biomarkers for AD staging. Some components of this figure were Created with BioRender.com and edited and combined with Inkscape. AD, Alzheimer disease; BIC, Bayesian information criteria; CSF, cerebrospinal fluid; DE, differential expression; MSBB, Mount Sinai Brain Bank; ROSMAP, Religious Orders Study and Memory and Aging Project.
Fig 1 Study design. . The transcriptomics, proteomics, metabolomics, and lipidomics profiles of postmortem parietal cortex samples from the Knight ADRC participants were used. The 3 omics shared 278 subjects (255 sporadic AD and 23 control cases). Expression/reading matrices were prepared for the same set of samples (n = 278) and different numbers of features (features = 60,754, proteins = 1,092, metabolites = 627). Before the integration, feature selection was performed on all omics datasets whose number of features exceeded 1,000 by selecting the top and most variant features. A Bayesian integrative clustering method was then employed to integrate the 3 omics datasets and the best clustering solution was extracted based on the maximum deviance ratio and the minimum BIC. AD molecular profiles were then linked to multiple clinical and molecular attributes to examine whether an association with these attributes exists. In addition, survival, DE, cell type-specific effect, and cell proportions inference analyses were performed on these profiles. These molecular profiles were then replicated in 2 independent datasets from MSBB BM36 (AD = 93, CO = 23) and ROSMAP (AD = 144, CO = 93). Dysregulated synaptic genes in the Knight-C4 profile were extracted and used for downstream AD staging analyses and in the ROSMAP cohort (early-AD vs. control and late-AD vs. control). Common synaptic genes present in the CSF SOMA dataset and associated with an increased risk of dementia through survival analyses were identified as CSF synaptic biomarkers for AD staging. Some components of this figure were Created with BioRender.com and edited and combined with Inkscape. AD, Alzheimer disease; BIC, Bayesian information criteria; CSF, cerebrospinal fluid; DE, differential expression; MSBB, Mount Sinai Brain Bank; ROSMAP, Religious Orders Study and Memory and Aging Project.CC BY · PubMed Central
Fig 2 Cross-omics data integration identified 4 distinct molecular profiles of AD associated with worse clinical outcomes and molecular attributes. (A) Heatmaps of multi-omics profiles of the top significant features. (B) Transcriptomic profiles (scaled) of the top genes contributed significantly to the clustering, showing an overall dysregulation of brains in Knight-C4. (C) The distribution of CDR scores across 4 clusters with Knight-C4 associated with high CDR scores. (D) Kaplan–Meier plots showing Knight-C4 association with poor outcome for the age of onset and death. (E) Boxplots showing the cell proportion from deconvolution analysis across 4 clusters using bulk RNA-seq from 4 cell types. Knight-C4 is associated with a significantly higher and lower proportion of astrocytes and neurons, respectively. (F) Boxplot showing each cluster’s first principal component of metabolomics profiles, with Knight-C2 and Knight-C4 showing a lower metabolomic signature than other AD cases. The data underlying panels C, E, and F can be found in S1 Data. AD, Alzheimer disease; CDR, Clinical Dementia Rating.
Fig 2 Cross-omics data integration identified 4 distinct molecular profiles of AD associated with worse clinical outcomes and molecular attributes. (A) Heatmaps of multi-omics profiles of the top significant features. (B) Transcriptomic profiles (scaled) of the top genes contributed significantly to the clustering, showing an overall dysregulation of brains in Knight-C4. (C) The distribution of CDR scores across 4 clusters with Knight-C4 associated with high CDR scores. (D) Kaplan–Meier plots showing Knight-C4 association with poor outcome for the age of onset and death. (E) Boxplots showing the cell proportion from deconvolution analysis across 4 clusters using bulk RNA-seq from 4 cell types. Knight-C4 is associated with a significantly higher and lower proportion of astrocytes and neurons, respectively. (F) Boxplot showing each cluster’s first principal component of metabolomics profiles, with Knight-C2 and Knight-C4 showing a lower metabolomic signature than other AD cases. The data underlying panels C, E, and F can be found in S1 Data. AD, Alzheimer disease; CDR, Clinical Dementia Rating.CC BY · PubMed Central
Fig 3 Molecular profiles of Knight-C4 are replicated in 2 independent datasets. (A) Heatmaps of the transcriptomic and proteomic profiles of the top features from MSBB (BM36) show 2 distinct clusters. (B) Boxplots showing MSBB-C1 associated with higher CDR scores, replicating Knight-C4 in the knight ADRC. (C) Boxplots showing cell proportions inferred from bulk RNA-seq from MSBB (BM36) using digital deconvolution. MSBB-C1 replicates Knight-C4 by showing an association with significantly higher and lower proportions of astrocytes and neurons, respectively. (D) Heatmap of the transcriptomic profiles of the top features from ROSMAP (DLPFC) showing 2 distinct clusters. I Boxplots showing ROSMAP-C1 associated with lower MMSE30 scores. (F) Boxplots showing cell proportion estimated from bulk RNA-seq from ROSMAP (DLPFC) using digital deconvolution. Like MSBB, ROSMAP-C1 replicates Knight-C4 by showing an association with significantly higher and lower proportions of astrocytes and neurons, respectively. (G) Venn diagram showing the common dysregulated genes in the discovery and replicated cohorts. (H) Heatmaps of the mean expression of the shared genes across the discovery and replicated cohorts showing a clear, consistent expression pattern. (I) Heatmap of the effect size detected in the discovery and replicated cohorts showing a high effect size similarity across the 3 cohorts. The data underlying panels B, C, E, and F can be found in S1 Data. CDR, Clinical Dementia Rating; DLPFC, dorsolateral prefrontal cortex; MSBB, Mount Sinai Brain Bank; ROSMAP, Religious Orders Study and Memory and Aging Project.
Fig 3 Molecular profiles of Knight-C4 are replicated in 2 independent datasets. (A) Heatmaps of the transcriptomic and proteomic profiles of the top features from MSBB (BM36) show 2 distinct clusters. (B) Boxplots showing MSBB-C1 associated with higher CDR scores, replicating Knight-C4 in the knight ADRC. (C) Boxplots showing cell proportions inferred from bulk RNA-seq from MSBB (BM36) using digital deconvolution. MSBB-C1 replicates Knight-C4 by showing an association with significantly higher and lower proportions of astrocytes and neurons, respectively. (D) Heatmap of the transcriptomic profiles of the top features from ROSMAP (DLPFC) showing 2 distinct clusters. I Boxplots showing ROSMAP-C1 associated with lower MMSE30 scores. (F) Boxplots showing cell proportion estimated from bulk RNA-seq from ROSMAP (DLPFC) using digital deconvolution. Like MSBB, ROSMAP-C1 replicates Knight-C4 by showing an association with significantly higher and lower proportions of astrocytes and neurons, respectively. (G) Venn diagram showing the common dysregulated genes in the discovery and replicated cohorts. (H) Heatmaps of the mean expression of the shared genes across the discovery and replicated cohorts showing a clear, consistent expression pattern. (I) Heatmap of the effect size detected in the discovery and replicated cohorts showing a high effect size similarity across the 3 cohorts. The data underlying panels B, C, E, and F can be found in S1 Data. CDR, Clinical Dementia Rating; DLPFC, dorsolateral prefrontal cortex; MSBB, Mount Sinai Brain Bank; ROSMAP, Religious Orders Study and Memory and Aging Project.CC BY · PubMed Central
Fig 4 The parietal cortex of participants with worse cognitive function exhibited remarkable molecular dysregulation. (A) Bar plots showing the significant genes detected in each cluster compared to the control. Yellow represents the total number of genes, green represents the cluster-specific genes, and purple depicts the number of genes missed with an unclustered approach (all AD cases vs. control). (B) Same as panel “A” but for proteins. (C) Same as panel “A” but for metabolites. (D) Race track plot showing the percentage of significant features for each cluster compared to other clusters for the 3 omics. (E) Venn diagrams showing the overlap between significant genes in Knight-C4 and synaptic genes (“synaptosome”) from Fei and colleagues [46]. (F) Same as “E” but overlaps with SynGO dataset [47]. The significance of overlap was computed using Fisher’s exact test. (G) Top 20 KEGG pathways associated with Knight-C4. (H) Top 20 GO biological process pathways associated with Knight-C4. The data underlying panels A, B, and C can be found in S1 Data. AD, Alzheimer disease.
Fig 4 The parietal cortex of participants with worse cognitive function exhibited remarkable molecular dysregulation. (A) Bar plots showing the significant genes detected in each cluster compared to the control. Yellow represents the total number of genes, green represents the cluster-specific genes, and purple depicts the number of genes missed with an unclustered approach (all AD cases vs. control). (B) Same as panel “A” but for proteins. (C) Same as panel “A” but for metabolites. (D) Race track plot showing the percentage of significant features for each cluster compared to other clusters for the 3 omics. (E) Venn diagrams showing the overlap between significant genes in Knight-C4 and synaptic genes (“synaptosome”) from Fei and colleagues [46]. (F) Same as “E” but overlaps with SynGO dataset [47]. The significance of overlap was computed using Fisher’s exact test. (G) Top 20 KEGG pathways associated with Knight-C4. (H) Top 20 GO biological process pathways associated with Knight-C4. The data underlying panels A, B, and C can be found in S1 Data. AD, Alzheimer disease.CC BY · PubMed Central
Fig 5 DE analyses identified ND genes associated with distinct clusters. (A) Volcano plot showing the up- and down-regulated genes identified between Knight-C4 vs. other clusters. Genes in red are examples of known ND genes. Genes in black are the top 10 significant genes based on the adjusted p-value and genes with log2(fold change) > 1. (B) Boxplots showing the transcriptomic profiles (in FPKM) of SNAP25 across 4 clusters (right) and for AD cases combined (left) in the Knight ADRC cohort. (C) Same as “B” but for GFAP. (D) Volcano plot showing the up-and down-regulated proteins identified between Knight-C2 vs. other clusters. (E) Boxplots showing the proteomic profiles of CLU across 4 clusters (right) and for all AD cases (left) in the Knight ADRC cohort. (F) Kaplan–Meier plot showing the association of Clusterin (ApoJ) protein concentrations in CSF with an increased risk of dementia progression using CDR change from 0 to 0.5 using the CSF dataset from the Knight ADRC participants. The data underlying panels B, C, and E can be found in S1 Data. AD, Alzheimer disease; CDR, Clinical Dementia Rating; CSF, cerebrospinal fluid; DE, differential expression; ND, neurodegenerative disease.
Fig 5 DE analyses identified ND genes associated with distinct clusters. (A) Volcano plot showing the up- and down-regulated genes identified between Knight-C4 vs. other clusters. Genes in red are examples of known ND genes. Genes in black are the top 10 significant genes based on the adjusted p-value and genes with log2(fold change) > 1. (B) Boxplots showing the transcriptomic profiles (in FPKM) of SNAP25 across 4 clusters (right) and for AD cases combined (left) in the Knight ADRC cohort. (C) Same as “B” but for GFAP. (D) Volcano plot showing the up-and down-regulated proteins identified between Knight-C2 vs. other clusters. (E) Boxplots showing the proteomic profiles of CLU across 4 clusters (right) and for all AD cases (left) in the Knight ADRC cohort. (F) Kaplan–Meier plot showing the association of Clusterin (ApoJ) protein concentrations in CSF with an increased risk of dementia progression using CDR change from 0 to 0.5 using the CSF dataset from the Knight ADRC participants. The data underlying panels B, C, and E can be found in S1 Data. AD, Alzheimer disease; CDR, Clinical Dementia Rating; CSF, cerebrospinal fluid; DE, differential expression; ND, neurodegenerative disease.CC BY · PubMed Central
Fig 6 Differential abundance analyses identified significant metabolites and pathways associated with Knight-C4. (A) Venn diagrams show the significantly increased and decreased metabolites shared between the Knight-C4 and ROSMAP-C1 compared to the control. The left and right boxes show the names of shared metabolites. (B) Similar to panel “A” but for metabolites shared between Knight-C4 and ROSMAP-C1 compared to the other cases. The significance of overlap was computed using Fisher’s exact test. ROSMAP, Religious Orders Study and Memory and Aging Project.
Fig 6 Differential abundance analyses identified significant metabolites and pathways associated with Knight-C4. (A) Venn diagrams show the significantly increased and decreased metabolites shared between the Knight-C4 and ROSMAP-C1 compared to the control. The left and right boxes show the names of shared metabolites. (B) Similar to panel “A” but for metabolites shared between Knight-C4 and ROSMAP-C1 compared to the other cases. The significance of overlap was computed using Fisher’s exact test. ROSMAP, Religious Orders Study and Memory and Aging Project.CC BY · PubMed Central
Fig 7 Integrating single-nuclei data with cross-omics profiles identified cell type-specific genes and pathways. (A) Bar plots showing the percentage of up- and down-regulated genes (clusters vs. control) identified in each cell type. (B) Top 20 KEGG pathways enriched in astrocytic up-regulated genes. (C) Top 20 GO biological process pathways enriched in neuronal down-regulated genes. (D) Top KEGG pathways enriched in neuronal down-regulated genes. (E) Boxplots show the transcriptomic profiles (in FPKM) of examples of cell type-specific genes identified in the Knight ADRC cohort. (F) The effect size of these examples was generated from single-nuclei data from the Knight ADRC participants. Red bars represent the cell type in which the gene is overexpressed. The data underlying panels A, E, and F can be found in S1 Data. DE, differential expression; OPC, oligodendrocyte precursor cell.
Fig 7 Integrating single-nuclei data with cross-omics profiles identified cell type-specific genes and pathways. (A) Bar plots showing the percentage of up- and down-regulated genes (clusters vs. control) identified in each cell type. (B) Top 20 KEGG pathways enriched in astrocytic up-regulated genes. (C) Top 20 GO biological process pathways enriched in neuronal down-regulated genes. (D) Top KEGG pathways enriched in neuronal down-regulated genes. (E) Boxplots show the transcriptomic profiles (in FPKM) of examples of cell type-specific genes identified in the Knight ADRC cohort. (F) The effect size of these examples was generated from single-nuclei data from the Knight ADRC participants. Red bars represent the cell type in which the gene is overexpressed. The data underlying panels A, E, and F can be found in S1 Data. DE, differential expression; OPC, oligodendrocyte precursor cell.CC BY · PubMed Central
Fig 8 Cross-omics integration identified alpha-synuclein levels down-regulated in AD participants with worse cognitive function common across multiple brain regions. (A) Transcriptomic profiles (in FPKM) of SNCA across 4 clusters (right) and for all AD cases (left) in the Knight ADRC cohort. (B) Proteomic profiles of SNCA across 4 clusters (right) and all AD cases (left) in the Knight ADRC cohort. (C) Transcriptomic profiles of SNCA across 4 clusters (right) and all AD cases (left) in the MSBB BM36 cohort. (D) Proteomic (TMT) profiles of SNCA across 4 clusters (right) and all AD cases (left) in the MSBB BM36 cohort. (E) Transcriptomic profiles of SNCA across 4 clusters (right) and all AD cases (left) in ROSMAP DLPFC cohort. The data underlying this figure can be found in S1 Data. AD, Alzheimer disease; DLPFC, dorsolateral prefrontal cortex; MSBB, Mount Sinai Brain Bank; ROSMAP, Religious Orders Study and Memory and Aging Project; TMT, tandem mass tag.
Fig 8 Cross-omics integration identified alpha-synuclein levels down-regulated in AD participants with worse cognitive function common across multiple brain regions. (A) Transcriptomic profiles (in FPKM) of SNCA across 4 clusters (right) and for all AD cases (left) in the Knight ADRC cohort. (B) Proteomic profiles of SNCA across 4 clusters (right) and all AD cases (left) in the Knight ADRC cohort. (C) Transcriptomic profiles of SNCA across 4 clusters (right) and all AD cases (left) in the MSBB BM36 cohort. (D) Proteomic (TMT) profiles of SNCA across 4 clusters (right) and all AD cases (left) in the MSBB BM36 cohort. (E) Transcriptomic profiles of SNCA across 4 clusters (right) and all AD cases (left) in ROSMAP DLPFC cohort. The data underlying this figure can be found in S1 Data. AD, Alzheimer disease; DLPFC, dorsolateral prefrontal cortex; MSBB, Mount Sinai Brain Bank; ROSMAP, Religious Orders Study and Memory and Aging Project; TMT, tandem mass tag.CC BY · PubMed Central
Fig 9 Synaptic dysregulation at multiple stages of AD identified CSF synaptic biomarkers for the molecular staging of AD. (A) Scatterplot showing the correlation of effect size between early-AD (EAD) and late-AD (AD) for common dysregulated synaptic genes in Knight-C4 and RSOSMAP. (B) Heatmap showing the effect size similarity of the most significant synaptic genes detected in early and late-AD. (C) Boxplots showing a consistent expression (transcriptomic) pattern between control, early-AD, and late-AD for genes IGF1, NRXN3, and YWHAZ. (D) Kaplan–Meier plots showing the association between IGF1, NRXN3, and YWHAZ genes and an increased risk of dementia progression using CSF proteomics data. The data underlying panel C can be found in S1 Data. AD, Alzheimer disease; CSF, cerebrospinal fluid.
Fig 9 Synaptic dysregulation at multiple stages of AD identified CSF synaptic biomarkers for the molecular staging of AD. (A) Scatterplot showing the correlation of effect size between early-AD (EAD) and late-AD (AD) for common dysregulated synaptic genes in Knight-C4 and RSOSMAP. (B) Heatmap showing the effect size similarity of the most significant synaptic genes detected in early and late-AD. (C) Boxplots showing a consistent expression (transcriptomic) pattern between control, early-AD, and late-AD for genes IGF1, NRXN3, and YWHAZ. (D) Kaplan–Meier plots showing the association between IGF1, NRXN3, and YWHAZ genes and an increased risk of dementia progression using CSF proteomics data. The data underlying panel C can be found in S1 Data. AD, Alzheimer disease; CSF, cerebrospinal fluid.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 8

  1. CF Lippa, 1999, Antibodies to α-synuclein detect Lewy bodies in many Down’s syndrome brains with Alzheimer’s disease., Ann Neurol, 45, 353, 10.1002/1531-8249(199903)45:3<353::AID-ANA11>3.0.CO;2-4 · doi:10.1002/1531-8249(199903)45:3<353::aid-ana11>3.0.co;2-4
  2. S. Andrews, 2010, FastQC: a quality control tool for high throughput sequence data., Babraham Bioinformatics, Babraham Institute, Cambridge, United Kingdom
  3. Picard Toolkit., 2019, Broad Institute, GitHub Repository.
  4. S Lê, 2008, FactoMineR: an R package for multivariate analysis, J Stat Softw, 25, 1
  5. T Hastie, 2018, impute: impute: Imputation for microarray data., R package version.
  6. Q Mo, 2013, iClusterPlus: integrative clustering of multiple genomic data sets
  7. T. Therneau, 2020, A Package for Survival Analysis in R., R package version 3.2–3
  8. A. Eklund, 2017, surviplot: Draw Survival Curves with Number-at-Risk., R package version 1.1.1

Cited by

See all 64

Metadata

Authors
Eteleeb, A. M., Novotny, B. C., Tarraga, C. S., Sohn, C., Dhungel, E., Brase, L., Nallapu, A., Buss, J., Farias, F., Bergmann, K., Bradley, J., Norton, J., Gentsch, J., Wang, F., Davis, A. A., Morris, J. C., Karch, C. M., Perrin, R. J., Benitez, B. A., & Harari, O.
Affiliations
  • Washington University in St. Louis (US)
  • University of North Carolina at Charlotte (US)
Corresponding author
  • Eteleeb, Abdallah M.
  • Novotny, Brenna C.
  • Sohn, Christopher
  • Dhungel, Eliza
  • Brase, Logan
  • Nallapu, Aasritha
  • Buss, Jared
  • Farias, Fabiana
  • Bergmann, Kristy
  • Bradley, Joseph
  • Norton, Joanne
  • Gentsch, Jen
  • Wang, Fengxian
  • Davis, Albert A.
  • Morris, John C.
  • Karch, Celeste M.
  • Perrin, Richard J.
  • Harari, Oscar
Venue
PLOS Biology
Published
2024-04-30
Volume
22
Issue
4
Pages
e3002607
ISSN
  • 1544-9173 (ISSN-L)
  • 1545-7885
OpenAlex
W4396506788
Cited by
64
References
187
Citations by year
2026: 37 · 2025: 24 · 2024: 3
FWCI
18.07
Type
journal article
Language
en
Open access
Locations
  • PLoS Biology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • National Institute on Aging (P30AG066444, P01AG003991, P01AG026276, R01AG057777, R01AG074012, U01AG072464, K01AG046374, R56AG067764, K25AG083057)
  • National Institute of Neurological Disorders and Stroke (R01NS118146, R21NS127211)
  • Chan Zuckerberg Initiative
  • Beth Israel Deaconess Medical Center (2023 Translational Hub Spark Grant Award)
  • Archer Foundation
  • Knight Alzheimer Disease Research Center (P30 AG066444)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Alzheimer's disease, molecular heterogeneity, transcriptomics, proteomics, metabolomics, lipidomics, astrocyte activation, synapse-related genes, mTOR signaling, endocytosis, phagosome, single-nucleus RNA sequencing, cell types, cerebrospinal fluid biomarkers, disease progression, cognitive decline, survival
MeSH terms
Machine Learning, Multiomics, Aged, Alzheimer Disease, Animals, Brain, Disease Models, Animal, Female, Humans, Male, Biomarkers, Disease Progression, Proteomics, Mice, Metabolomics, Transcriptome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.